Login to Your Account



Gilead's Atripla, Lower Costs Provide Lift To First Quarter

By Randall Osborne


Monday, April 23, 2007
Gilead Sciences Inc.'s HIV steamroller charged on, helped by strong sales of Atripla in the first quarter (though Truvada and Viread dipped) plus lowered expenses, and the firm bolstered its position in antibiotics with Phase III data on inhaled aztreonam lysine for cystic fibrosis patients with pulmonary Pseudomonas aeruginosa. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription